Skip to main content

Publisher: Wiley-Blackwell on behalf of the International Society on Thrombosis and Haemostasis

Volume 10, Number 10, 1 October 2012

Free Content Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results
pp. 1979-1987(9)
Authors: PENGO, V.; CRIPPA, L.; FALANGA, A.; FINAZZI, G.; MARONGIU, F.; MOIA, M.; PALARETI, G.; POLI, D.; TESTA, S.; TIRAFERRI, E.; TOSETTO, A.; TRIPODI, A.; SIRAGUSA, S.; MANOTTI, C.

Favourites:
ADD

Free Content Contemporary management of primary immune thrombocytopenia in adults
pp. 1988-1998(11)
Authors: LAKSHMANAN, S.; CUKER, A.

Favourites:
ADD

Free Content Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrel
pp. 1999-2005(7)
Authors: BONELLO, L.; MANCINI, J.; PANSIERI, M.; MAILLARD, L.; ROSSI, P.; COLLET, F.; JOUVE, B.; WITTENBERG, O.; LAINE, M.; MICHELET, P.; BESSEREAU, J.; LEMESLE, G.; DIGNAT‐GEORGE, F.; PAGANELLI, F.; CAMOIN‐JAU, L.

Favourites:
ADD

Free Content Safety and efficacy of protease‐activated receptor‐1 antagonists in patients with coronary artery disease: a meta‐analysis of randomized clinical trials
pp. 2006-2015(10)
Authors: CAPODANNO, D.; BHATT, D. L.; GOTO, S.; O’DONOGHUE, M. L.; MOLITERNO, D. J.; TAMBURINO, C.; ANGIOLILLO, D. J.

Favourites:
ADD
Favourites:
ADD

Free Content PROC c.574_576del polymorphism: a common genetic risk factor for venous thrombosis in the Chinese population
pp. 2019-2026(8)
Authors: TANG, L.; LU, X.; YU, J. M.; WANG, Q. Y.; YANG, R.; GUO, T.; MEI, H.; HU, Y.

Favourites:
ADD
Favourites:
ADD

Free Content Risk factors and clinical outcome of unsuspected pulmonary embolism in cancer patients: a case‐control study
pp. 2032-2038(7)
Authors: SAHUT D’IZARN, M.; CAUMONT PRIM, A.; PLANQUETTE, B.; REVEL, M. P.; AVILLACH, P.; CHATELLIER, G.; SANCHEZ, O.; MEYER, G.

Favourites:
ADD

Free Content Risk of post‐thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study
pp. 2039-2044(6)
Authors: CHITSIKE, R. S.; RODGER, M. A.; KOVACS, M. J.; BETANCOURT, M. T.; WELLS, P. S.; ANDERSON, D. R.; CHAGNON, I.; LE GAL, G.; SOLYMOSS, S.; CROWTHER, M. A.; PERRIER, A.; WHITE, R. H.; VICKARS, L. M.; RAMSAY, T.; KAHN, S. R.

Favourites:
ADD

Free Content Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO‐TEP registry
pp. 2045-2052(8)
Authors: BEYER‐WESTENDORF, J.; LÜTZNER, J.; DONATH, L.; RADKE, O. C.; KUHLISCH, E.; HARTMANN, A.; WEISS, N.; WERTH, S.

Favourites:
ADD

Free Content Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes?
pp. 2053-2060(8)
Authors: SHARMA, A.; CHATTERJEE, S.; LICHSTEIN, E.; MUKHERJEE, D.

Favourites:
ADD

Free Content Sex hormone‐binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives
pp. 2061-2067(7)
Authors: STEGEMAN, B.H.; HELMERHORST, F. M.; VOS, H. L.; ROSENDAAL, F. R.; VAN HYLCKAMA VLIEG, A.

Favourites:
ADD

Free Content Cigarette smoking and the risk of venous thromboembolism: The Tromsø Study
pp. 2068-2074(7)
Authors: ENGA, K. F.; BRÆKKAN, S. K.; HANSEN‐KRONE, I. J.; le CESSIE, S.; ROSENDAAL, F. R.; HANSEN, J.‐B.

Favourites:
ADD

Free Content Low‐dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta‐analysis of the literature
pp. 2075-2085(11)
Authors: DENTALI, F.; AGENO, W.; REZOAGLI, E.; RANCAN, E.; SQUIZZATO, A.; MIDDELDORP, S.; MARGAGLIONE, M.; GRANDONE, E.

Favourites:
ADD

Free Content A possible mechanism for Inv22‐related F8 large deletions in severe hemophilia A patients with high responding factor VIII inhibitors
pp. 2099-2107(9)
Authors: FUJITA, J.; MIYAWAKI, Y.; SUZUKI, A.; MAKI, A.; OKUYAMA, E.; MURATA, M.; TAKAGI, A.; MURATE, T.; SUZUKI, N.; MATSUSHITA, T.; SAITO, H.; KOJIMA, T.

Favourites:
ADD

Free Content Immobilized transition metal ions stimulate contact activation and drive factor XII‐mediated coagulation
pp. 2108-2115(8)
Authors: MUTCH, N. J.; WATERS, E. K.; MORRISSEY, J. H.

Favourites:
ADD

Free Content Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests
pp. 2116-2122(7)
Authors: RIJKEN, D. C.; KOCK, E. L.; GUIMARÃES, A. H. C.; TALENS, S.; MURAD, S. DARWISH; JANSSEN, H. L. A.; LEEBEEK, F. W. G.

Favourites:
ADD

Free Content Antithrombotic phosphoinositide 3‐kinase β inhibitors in humans: a ‘shear’ delight!
pp. 2123-2126(4)
Authors: JACKSON, S. P.; SCHOENWAELDER, S. M.

Favourites:
ADD

Free Content Human target validation of phosphoinositide 3‐kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor
pp. 2127-2136(10)
Authors: NYLANDER, S.; KULL, B.; BJÖRKMAN, J. A.; ULVINGE, J. C.; OAKES, N.; EMANUELSSON, B. M.; ANDERSSON, M.; SKÄRBY, T.; INGHARDT, T.; FJELLSTRÖM, O.; GUSTAFSSON, D.

Favourites:
ADD

Free Content Fibrinogen γ‐chain peptide‐coated, ADP‐encapsulated liposomes rescue thrombocytopenic rabbits from non‐compressible liver hemorrhage
pp. 2137-2148(12)
Authors: NISHIKAWA, K.; HAGISAWA, K.; KINOSHITA, M.; SHONO, S.; KATSUNO, S.; DOI, M.; YANAGAWA, R.; SUZUKI, H.; IWAYA, K.; SAITOH, D.; SAKAMOTO, T.; SEKI, S.; TAKEOKA, S.; HANDA, M.

Favourites:
ADD

Free Content Increased platelet activation and thrombosis in transgenic mice expressing constitutively active P2Y12
pp. 2149-2157(9)
Authors: ZHANG, Y.; YE, J.; HU, L.; ZHANG, S.; ZHANG, S. H.; LI, Y.; KUNAPULI, S. P.; DING, Z.

Favourites:
ADD

Free Content Formation of platelet‐binding von Willebrand factor strings on non‐endothelial cells
pp. 2168-2178(11)
Authors: WANG, J. W.; VALENTIJN, J. A.; VALENTIJN, K. M.; DRAGT, B. S.; VOORBERG, J.; REITSMA, P. H.; EIKENBOOM, J.

Favourites:
ADD

Free Content An international study on the standardization of fibrin clot permeability measurement: methodological considerations and implications for healthy control values
pp. 2179-2181(3)
Authors: PIETERS, M.; UNDAS, A.; MARCHI, R.; DE MAAT, M. P. M.; WEISEL, J. W.; ARIËNS, R. A. S.; ON BEHALF OF THE FACTOR XIII AND FIBRINOGEN SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDISATION COMMITTEE OF THE INTERNATIONAL SOCIETY FOR THROMBOSIS AND HAEMOSTASIScr7

Favourites:
ADD

Free Content Standardization of post‐thrombotic syndrome definition and outcome assessment following upper venous system thrombosis in pediatric practice
pp. 2182-2185(4)
Authors: REVEL‐VILK, S.; BRANDÃO, L. R.; JOURNEYCAKE, J.; GOLDENBERG, A.; MONAGLE, P.; SHARATHKUMAR, A.; CHAN, A. K. C.; ON BEHALF OF THE PERINATAL AND PAEDIATRIC HAEMOSTASIS SUBCOMMITTEE OF THE SCIENTIFIC AND STANDARDIZATION COMMITTEE OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND HAEMOSTASIScr8

Favourites:
ADD

Free Content Etiology of venous thrombosis: the need for small original studies
pp. 2189-2190(2)
Author: ROSENDAAL, F. R.

Favourites:
ADD

Free Content Interaction between blood type, smoking and factor V Leiden mutation and risk of venous thromboembolism: a Danish case‐cohort study
pp. 2191-2193(3)
Authors: EL‐GALALY, T. C.; KRISTENSEN, S. R.; OVERVAD, K.; STEFFENSEN, R.; TJØNNELAND, A.; SEVERINSEN, M. T.

Favourites:
ADD

Free Content Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
pp. 2194-2196(3)
Authors: HERMANS, C.; ASTERMARK, J.; DE MOERLOOSE, P.

Favourites:
ADD

Free Content Dissecting pharmacodynamics to determine the optimal sampling time and measurement for assessing the antiplatelet effect of clopidogrel
pp. 2196-2199(4)
Authors: KIM, S.‐D.; JEONG, Y.‐H.; LEE, S.‐W.; SHIN, I. H.; PARK, J.‐Y.; PARK, S.‐W.; YOON, Y.‐R.; SONG, J.‐K.

Favourites:
ADD

Free Content The impact of smoking on the antiplatelet action of clopidogrel in non‐ST‐elevation myocardial infarction patients: results from the ISAR‐REACT 4 platelet substudy
pp. 2199-2202(4)
Authors: SIBBING, D.; BERNLOCHNER, I.; SCHULZ, S.; MASSBERG, S.; SCHÖMIG, A.; MEHILLI, J.; KASTRATI, A.

Favourites:
ADD

Free Content Thrombin induces de novo protein synthesis of stromal cell‐derived factor‐1α but not angiostatin in human platelets
pp. 2202-2205(4)
Authors: HUANG, Z.; RAHMAN, M. F.‐U.; JIANG, L.; XIE, H.; HU, H.; LUI, W.‐O.; LI, N.

Favourites:
ADD

Free Content Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study
pp. 2205-2206(2)
Authors: MILAN, M.; NOVENTA, F.; GHIRARDUZZI, A.; PENGO, V.; VEDOVETTO, V.; FILIPPI, L.; CAMPELLO, E.; PRANDONI, P.

Favourites:
ADD

Free Content Impaired tissue factor pathway inhibitor function is associated with recurrent venous thromboembolism in patients with first unprovoked deep venous thrombosis
pp. 2208-2211(4)
Authors: WINCKERS, K.; TEN CATE‐HOEK, A. J.; BEEKERS, K. C. M. M.; ERKENS, P.; HAMULYÁK, K.; TEN CATE, H.; HACKENG, T. M.

Favourites:
ADD

Free Content Join ISTH
pp. 2213-2214(2)

Favourites:
ADD

  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more